atezolizumab,trastuzumab,pertuzumab,trastuzumab emtansine
roche,daiichi sankyo
 not too surprising, as it is in line with the failures of io in her2+ mbc. one more reminder of the biological heterogeneity of breast cancer &amp; its immunological correlates!
MD, Research Fellow @DanaFarber | @harvardmed | @IEOufficiale | @LaStatale. Interested in breast oncology, HER2, ADCs & good music. Coffee expert.